Skip to content
Research Atlas / Field

Rare pediatric cancer

4 questions in the Atlas. 1 still open. Know something we don't? Send us a problem.

In this field

4 questions, strongest case first

  1. Can the survival curves printed in decades of small DIPG (diffuse intrinsic pontine glioma) trials be turned back into approximate patient-level data and pooled into one open, shared control group, so that the field can see whether any added treatment ever beat radiotherapy alone and can judge new single-arm trials against a fair benchmark?DIPG trials are small, mostly single-arm and very varied, so they are rarely pooled properly.
  2. Predicting which medicines reach the tumor in DIPGParked, not rejected: the premise that the brainstem barrier is tighter is contested in the published evidence, and there is almost no paired brainstem-versus-cortex drug measurement to train or test a model on (one human DIPG tumour measurement exists), so Checkable is 2.
  3. Better computer ranking of medicine pairs for DIPGRejected on prior art and target validity: in-dish synergy, the label a pair ranking would learn, has not predicted benefit in animal models in this disease or pan-cancer; public combination data are essentially one cell line around two anchor drugs; and funded groups with labs already design combinations by other methods.
  4. For the more than 100 drugs that the US National Cancer Institute's pediatric programs have tested in mice carrying childhood tumours since 2004, how well did the mouse results predict which drugs later helped or failed in children's trials, and which features of the mouse test (share of tumours that shrank, whether the mouse drug exposure was reachable in children, drug class) carry the signal?Parked: no drug-by-drug, whole-dataset comparison of PPTP/PPTC mouse results with children's trial outcomes exists (the 2024 review's tables are mouse-only; the outside 'fatal' was not upheld), but likely fewer than 10 clinical successes, selection bias in which drugs reached children, and no exposure data in the public spreadsheet put the predictive question out of reach; only a small descriptive table is feasible, and the NCI PIVOT team holds the data.

Other fields